Skip to main content

Peer Review reports

From: Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

Original Submission
10 Mar 2022 Submitted Original manuscript
22 Apr 2022 Reviewed Reviewer Report
22 Apr 2022 Reviewed Reviewer Report
25 Apr 2022 Reviewed Reviewer Report - Laura Atzori
1 May 2022 Reviewed Reviewer Report
1 May 2022 Reviewed Reviewer Report
31 May 2022 Author responded Author comments - Maartje Rohaan
Resubmission - Version 2
31 May 2022 Submitted Manuscript version 2
15 Jun 2022 Reviewed Reviewer Report
24 Jun 2022 Reviewed Reviewer Report
8 Jul 2022 Author responded Author comments - Maartje Rohaan
Resubmission - Version 3
8 Jul 2022 Submitted Manuscript version 3
Publishing
13 Jul 2022 Editorially accepted
4 Aug 2022 Article published 10.1186/s12885-022-09896-4

You can find further information about peer review here.

Back to article page